MDL Judge Finds Celebrex 200-Mg Data Unreliable Under Daubert
Friday, November 30th, 2007SAN FRANCISCO - The federal judge supervising consolidated litigation over Pfizer Inc.’s COX-2 inhibiting painkillers has ruled that plaintiffs’ generic evidence for cardiovascular injury from 200 milligrams or less of Celebrex daily does not meet the reliability requirements of Daubert v. Merrell Dow Pharmaceuticals, Inc. (509 U.S. 579 [1993]) (In Re: Bextra and Celebrex Marketing […]

